PMID- 23154126
OWN - NLM
STAT- MEDLINE
DCOM- 20130222
LR  - 20171114
IS  - 1468-330X (Electronic)
IS  - 0022-3050 (Linking)
VI  - 84
IP  - 1
DP  - 2013 Jan
TI  - Changes in quality of life scores with intravenous immunoglobulin or 
      plasmapheresis in patients with myasthenia gravis.
PG  - 94-7
LID - 10.1136/jnnp-2011-301449 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) and plasmapheresis (plasma exchange 
      (PLEX)) have comparable efficacy in reducing the Quantitative Myasthenia Gravis 
      Score for disease severity (QMGS) in patients with moderate to severe myasthenia 
      gravis (MG). OBJECTIVE: To determine if the improvement in the quality of life 
      (QOL) after immunomodulation is comparable with either IVIG or PLEX. METHODS: 62 
      patients participated in the MG-QOL-60 study, completing the questionnaire at 
      baseline and at day 14 after treatment. The MG-QOL-15 scores were computed from 
      the MG-QOL-60 questionnaire responses. We analysed the change in the QOL scores 
      from baseline to day 14 in both treatment groups. RESULTS: The scores in both QOL 
      scales decreased at day 14 in the IVIG and PLEX groups, without significant 
      difference between groups (QOL-15: IVIG -5.7 +/- 8.5, PLEX: -7.0 +/- 7.6, p=0.52; 
      QOL-60: IVIG -13.3 +/- 16.9, PLEX -18.5 +/- 22.0, p = 0.41). The improvement in QOL 
      showed a good correlation with the decrease in QMGS. There was an excellent 
      correlation between the MG-QOL-15 and MG-QOL-60 scores at baseline and at day 14. 
      CONCLUSIONS: This study of MG-QOL changes supports recent findings that IVIG and 
      PLEX are comparable in the treatment of patients with moderate to severe MG and 
      worsening symptoms. Furthermore, our study supports the use of the MG-QOL-15 as a 
      secondary outcome measure in future clinical trials in MG.
FAU - Barnett, Carolina
AU  - Barnett C
AD  - Department of Medicine, Division of Neurology, Toronto General Hospital, 5EC-309, 
      200 Elizabeth St, Toronto, ON M5G 2C4, Canada.
FAU - Wilson, Graham
AU  - Wilson G
FAU - Barth, David
AU  - Barth D
FAU - Katzberg, Hans D
AU  - Katzberg HD
FAU - Bril, Vera
AU  - Bril V
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20121115
PL  - England
TA  - J Neurol Neurosurg Psychiatry
JT  - Journal of neurology, neurosurgery, and psychiatry
JID - 2985191R
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Myasthenia Gravis/*drug therapy/psychology/*therapy
MH  - Plasmapheresis/methods/*psychology
MH  - Quality of Life/*psychology
MH  - Single-Blind Method
MH  - Surveys and Questionnaires
EDAT- 2012/11/17 06:00
MHDA- 2013/02/23 06:00
CRDT- 2012/11/17 06:00
PHST- 2012/11/17 06:00 [entrez]
PHST- 2012/11/17 06:00 [pubmed]
PHST- 2013/02/23 06:00 [medline]
AID - jnnp-2011-301449 [pii]
AID - 10.1136/jnnp-2011-301449 [doi]
PST - ppublish
SO  - J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):94-7. doi: 
      10.1136/jnnp-2011-301449. Epub 2012 Nov 15.